Influenza
Conditions
Keywords
Vaccine, Elderly, Influenza
Brief summary
This clinical trial aims to study the immunogenicity of GSK Biologicals' influenza vaccine GSK2186877A in people aged 65 years or older.
Detailed description
The amendment to the protocol posting: minor change in one inclusion criterion and in one secondary outcome measure.
Interventions
BIOLOGICALGSK Biologicals' influenza vaccine GSK2186877A
One intramuscular injection at Day 0
BIOLOGICALGSK Biologicals' Fluarix
One intramuscular injection at Day 0
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
All subjects must satisfy the following criteria at study entry: * Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study. Specific attention should be given to the compliance potential of subjects with suspected or known drug or alcohol abuse. * Written informed consent obtained from the subject. * Free of an acute aggravation of the health status as established by medical history and clinical examination before entering into the study. Elderly adults: • A man or woman 65 year of age or older at the time of the first vaccination. Young adults: * Man or woman between the ages of 18 and 40 years, inclusive. * If the subject is female, she must be of non-childbearing potential or be post-menopausal, or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for 2 months after vaccination.
Exclusion criteria
* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days prior to vaccination, or planned use during the study period. * Administration of other licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrolment in this study. Planned administration of a vaccine not foreseen by the study protocol up to Visit 4 after vaccination and of an influenza vaccine other than the study vaccines up to Visit 4. * Vaccination against influenza since February 2008 with a seasonal influenza vaccine. * Previous vaccination in the last three years with an investigational adjuvanted vaccine candidate seasonal or pandemic influenza vaccine. * Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. * Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination. * History of hypersensivity to a previous dose of influenza vaccine. * History of allergy or reactions likely to be exacerbated by any component of the vaccine(s) including egg or chicken protein. * Acute (active) clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by clinical evaluation or pre-existing laboratory screening tests. * Acute disease at the time of enrolment. * Administration of immunoglobulins and/or any blood products within the three months preceding the first administration of the study vaccine or planned administration during the study. * Any medical conditions in which intramuscular injections are contraindicated. * Pregnant or lactating female. * Female of childbearing age planning to become pregnant or planning to discontinue contraceptive precautions. * Any medical condition that in the opinion of the investigator precludes the collection of blood volumes as required by the protocol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains Which Are Producing at Least Two Different Markers | Day 21 | The markers assessed were Cluster of Differentiation 40 Ligand (CD40L), interleukin-2 (IL-2), tumor necrosis factor alpha (TNF-α), interferon-gamma (IFN-γ) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | At Day 0, 21, 42 and 180 | The markers assessed were CD40L, IL-2, TNF-α, IFN-γ. The separate vaccine strains tested included A/Brisbane, A/Uruguay, B/Brisbane antigens. |
| Haemagglutinin Inhibition (HI) Antibody Titers | At Day 0, 21, 42 and 180 | Antibody titers were expressed as Geometric mean titers (GMTs) calculated after invitro stimulation with separate vaccine strains. |
| The Number of Subjects Seropositive to HI Antibodies Calculated After in Vitro Stimulation With Separate Vaccine Strains. | At Day 0, 21, 42 and 180 | Seropositivity was defined as antibody titer greater than or equal to the cut-off value i.e ≥ 1:10 |
| The Number of Subjects Seroconverted to HI Antibodies | At Day 21, 42 and 180 | Seroconversion was defined as the number of vaccinees who had either a prevaccination titer \< 1:10 and a post-vaccination titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and at least a 4-fold increase in post-vaccination titer. |
| HI Antibody Seroconversion Factors | At Day 21, 42 and 180 | Seroconversion factors were defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0. |
| The Number of Subjects Seroprotected to HI Antibodies | At Day 0, 21, 42 and 180 | A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to 1:40 that usually is accepted as indicating protection. |
| Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Day 0 -6 | Grade 3 ecchymosis, redness and swelling was \>100mm and grade 3 pain was considerable pain at rest, that prevented normal everyday activity. |
| The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | At Day 0, 21, 42 and 180 | The markers assessed were CD40L, IL-2, TNF-α, IFN-γ. The separate vaccine strains tested included A/Brisbane, A/Uruguay, B/Brisbane antigens. |
| Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Day 0 -6 | Any fever was defined as oral temperature ≥ 38.0 degree centigrade (°C), grade 3 fever was defined as oral temperature ≥ 39.0°C. For other symptoms grade 3 was defined as general symptom that prevented normal activity and related was general symptom assessed by the investigator as causally related to the study vaccination. |
| Duration of Solicited General AEs | Day 0 -6 | Duration was defined as number of days with any grade of general symptoms. |
| Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Day 0-20 | Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom, regardless of intensity or relation to vaccination, grade 3 was unsolicited symptom that prevented normal activity and related was event assessed by investigator as causally related to the study vaccination. |
| Number of Subjects Reporting Any, Grade 3 and Related AEs With a Medically Attended Visit (MAEs) | Day 0-179 | For each solicited and unsolicited AE the subject experienced, the subject was asked if they received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as occurrence of any symptom, regardless of intensity or relation to vaccination, grade 3 was defined as symptom that prevented normal activity and related was event assessed by investigator as causally related to the study vaccination. |
| Number of Subjects Reporting Any AEs of Specific Interest (AESI) | Day 0-364 | AESI for safety monitoring are a subset of AEs that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology. Any was defined as occurrence of any symptom, regardless of intensity or relation to vaccination. |
| Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) | Day 0-364 | SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom, regardless of intensity or relation to vaccination and related was event assessed by investigator as causally related to the study vaccination. |
| Duration of Solicited Local AEs | Day 0 -6 | Duration was defined as the number of days with any grade of local symptoms. |
Countries
Spain, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| New Generation Influenza Vaccine GSK2186877A Group Subjects aged ≥ 65 years receiving 1 dose of New generation influenza vaccine GSK2186877A at Day 0 | 69 |
| Fluarix Elderly Group Subjects aged \>= 65 years receiving 1 dose of Fluarix vaccine at Day 0 | 73 |
| Fluarix Young Group Subjects aged 18-40 years receiving 1 dose of Fluarix vaccine at Day 0 | 50 |
| Total | 192 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Adverse Event | 1 | 0 | 0 |
| Overall Study | Withdrawal by Subject | 0 | 0 | 1 |
Baseline characteristics
| Characteristic | New Generation Influenza Vaccine GSK2186877A Group | Fluarix Elderly Group | Fluarix Young Group | Total |
|---|---|---|---|---|
| Age, Continuous | 71.5 Years STANDARD_DEVIATION 5.44 | 71.5 Years STANDARD_DEVIATION 5.32 | 26.0 Years STANDARD_DEVIATION 4.91 | 59.7 Years STANDARD_DEVIATION 20.69 |
| Sex: Female, Male Female | 36 Participants | 29 Participants | 27 Participants | 92 Participants |
| Sex: Female, Male Male | 33 Participants | 44 Participants | 23 Participants | 100 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 53 / 69 | 27 / 73 | 43 / 50 |
| serious Total, serious adverse events | 5 / 69 | 11 / 73 | 1 / 50 |
Outcome results
Primary
The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains Which Are Producing at Least Two Different Markers
The markers assessed were Cluster of Differentiation 40 Ligand (CD40L), interleukin-2 (IL-2), tumor necrosis factor alpha (TNF-α), interferon-gamma (IFN-γ)
Time frame: Day 21
Population: Analysis was performed on According-to-Protocol (ATP) Immunogenicity cohort. This cohort included all evaluable subjects for whom data concerning immunogenicity were available. Analysis was only performed for New generation influenza vaccine GSK2186877A Group and Fluarix elderly Group.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| New Generation Influenza Vaccine GSK2186877A Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains Which Are Producing at Least Two Different Markers | 3371.11 cells per million CD4+ Tcells | Standard Deviation 3602.15 |
| Fluarix Elderly Group | The Geometric Mean (GM) Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains Which Are Producing at Least Two Different Markers | 2108.10 cells per million CD4+ Tcells | Standard Deviation 1728.38 |
Secondary
Duration of Solicited General AEs
Duration was defined as number of days with any grade of general symptoms.
Time frame: Day 0 -6
Population: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented on subjects who experienced the symptom.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| New Generation Influenza Vaccine GSK2186877A Group | Duration of Solicited General AEs | Fever | 2.0 Days |
| New Generation Influenza Vaccine GSK2186877A Group | Duration of Solicited General AEs | Arthralgia | 2.0 Days |
| New Generation Influenza Vaccine GSK2186877A Group | Duration of Solicited General AEs | Gastrointestinal symptoms | 1.0 Days |
| New Generation Influenza Vaccine GSK2186877A Group | Duration of Solicited General AEs | Headache | 1.0 Days |
| New Generation Influenza Vaccine GSK2186877A Group | Duration of Solicited General AEs | Myalgia | 2.0 Days |
| New Generation Influenza Vaccine GSK2186877A Group | Duration of Solicited General AEs | Shivering | 1.0 Days |
| New Generation Influenza Vaccine GSK2186877A Group | Duration of Solicited General AEs | Fatigue | 2.0 Days |
| Fluarix Elderly Group | Duration of Solicited General AEs | Gastrointestinal symptoms | 2.0 Days |
| Fluarix Elderly Group | Duration of Solicited General AEs | Headache | 2.0 Days |
| Fluarix Elderly Group | Duration of Solicited General AEs | Arthralgia | 2.0 Days |
| Fluarix Elderly Group | Duration of Solicited General AEs | Fatigue | 2.5 Days |
| Fluarix Elderly Group | Duration of Solicited General AEs | Myalgia | 1.5 Days |
| Fluarix Young Group | Duration of Solicited General AEs | Shivering | 2.5 Days |
| Fluarix Young Group | Duration of Solicited General AEs | Fatigue | 2.0 Days |
| Fluarix Young Group | Duration of Solicited General AEs | Gastrointestinal symptoms | 1.0 Days |
| Fluarix Young Group | Duration of Solicited General AEs | Myalgia | 1.0 Days |
| Fluarix Young Group | Duration of Solicited General AEs | Arthralgia | 1.5 Days |
| Fluarix Young Group | Duration of Solicited General AEs | Headache | 1.5 Days |
Secondary
Duration of Solicited Local AEs
Duration was defined as the number of days with any grade of local symptoms.
Time frame: Day 0 -6
Population: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented on subjects who experienced the symptom.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| New Generation Influenza Vaccine GSK2186877A Group | Duration of Solicited Local AEs | Ecchymosis | 3.5 Days |
| New Generation Influenza Vaccine GSK2186877A Group | Duration of Solicited Local AEs | Redness | 2.0 Days |
| New Generation Influenza Vaccine GSK2186877A Group | Duration of Solicited Local AEs | Swelling | 4.0 Days |
| New Generation Influenza Vaccine GSK2186877A Group | Duration of Solicited Local AEs | Pain | 2.0 Days |
| Fluarix Elderly Group | Duration of Solicited Local AEs | Swelling | 5.0 Days |
| Fluarix Elderly Group | Duration of Solicited Local AEs | Ecchymosis | 5.0 Days |
| Fluarix Elderly Group | Duration of Solicited Local AEs | Pain | 1.0 Days |
| Fluarix Young Group | Duration of Solicited Local AEs | Pain | 2.0 Days |
Secondary
Haemagglutinin Inhibition (HI) Antibody Titers
Antibody titers were expressed as Geometric mean titers (GMTs) calculated after invitro stimulation with separate vaccine strains.
Time frame: At Day 0, 21, 42 and 180
Population: The analysis of immunogenicity was performed on According-to-Protocol (ATP) Immunogenicity cohort which included all evaluable subjects for whom data concerning immunogenicity data were available.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| New Generation Influenza Vaccine GSK2186877A Group | Haemagglutinin Inhibition (HI) Antibody Titers | A/Brisbane strain at Day 0 | 16.5 titer |
| New Generation Influenza Vaccine GSK2186877A Group | Haemagglutinin Inhibition (HI) Antibody Titers | A/Brisbane strain at Day 21 | 105.1 titer |
| New Generation Influenza Vaccine GSK2186877A Group | Haemagglutinin Inhibition (HI) Antibody Titers | A/Brisbane strain at Day 42 | 82.3 titer |
| New Generation Influenza Vaccine GSK2186877A Group | Haemagglutinin Inhibition (HI) Antibody Titers | A/Brisbane strain at Day 180 | 38.4 titer |
| New Generation Influenza Vaccine GSK2186877A Group | Haemagglutinin Inhibition (HI) Antibody Titers | A/Uruguay strain at Day 0 | 21.4 titer |
| New Generation Influenza Vaccine GSK2186877A Group | Haemagglutinin Inhibition (HI) Antibody Titers | A/Uruguay strain at Day 21 | 330.9 titer |
| New Generation Influenza Vaccine GSK2186877A Group | Haemagglutinin Inhibition (HI) Antibody Titers | A/Uruguay strain at Day 42 | 254.8 titer |
| New Generation Influenza Vaccine GSK2186877A Group | Haemagglutinin Inhibition (HI) Antibody Titers | A/Uruguay strain at Day 180 | 117.0 titer |
| New Generation Influenza Vaccine GSK2186877A Group | Haemagglutinin Inhibition (HI) Antibody Titers | B/Brisbane strain at Day 0 | 92.0 titer |
| New Generation Influenza Vaccine GSK2186877A Group | Haemagglutinin Inhibition (HI) Antibody Titers | B/Brisbane strain at Day 21 | 699.9 titer |
| New Generation Influenza Vaccine GSK2186877A Group | Haemagglutinin Inhibition (HI) Antibody Titers | B/Brisbane strain at Day 42 | 487.2 titer |
| New Generation Influenza Vaccine GSK2186877A Group | Haemagglutinin Inhibition (HI) Antibody Titers | B/Brisbane strain at Day 180 | 254.5 titer |
| Fluarix Elderly Group | Haemagglutinin Inhibition (HI) Antibody Titers | B/Brisbane strain at Day 180 | 238.4 titer |
| Fluarix Elderly Group | Haemagglutinin Inhibition (HI) Antibody Titers | A/Brisbane strain at Day 0 | 14.3 titer |
| Fluarix Elderly Group | Haemagglutinin Inhibition (HI) Antibody Titers | A/Uruguay strain at Day 42 | 110.1 titer |
| Fluarix Elderly Group | Haemagglutinin Inhibition (HI) Antibody Titers | B/Brisbane strain at Day 0 | 97.0 titer |
| Fluarix Elderly Group | Haemagglutinin Inhibition (HI) Antibody Titers | A/Brisbane strain at Day 21 | 67.2 titer |
| Fluarix Elderly Group | Haemagglutinin Inhibition (HI) Antibody Titers | A/Uruguay strain at Day 21 | 164.2 titer |
| Fluarix Elderly Group | Haemagglutinin Inhibition (HI) Antibody Titers | B/Brisbane strain at Day 42 | 393.9 titer |
| Fluarix Elderly Group | Haemagglutinin Inhibition (HI) Antibody Titers | A/Brisbane strain at Day 42 | 56.8 titer |
| Fluarix Elderly Group | Haemagglutinin Inhibition (HI) Antibody Titers | A/Uruguay strain at Day 180 | 59.9 titer |
| Fluarix Elderly Group | Haemagglutinin Inhibition (HI) Antibody Titers | A/Uruguay strain at Day 0 | 17.5 titer |
| Fluarix Elderly Group | Haemagglutinin Inhibition (HI) Antibody Titers | A/Brisbane strain at Day 180 | 32.1 titer |
| Fluarix Elderly Group | Haemagglutinin Inhibition (HI) Antibody Titers | B/Brisbane strain at Day 21 | 502.6 titer |
| Fluarix Young Group | Haemagglutinin Inhibition (HI) Antibody Titers | A/Brisbane strain at Day 180 | 90.3 titer |
| Fluarix Young Group | Haemagglutinin Inhibition (HI) Antibody Titers | A/Uruguay strain at Day 0 | 16.4 titer |
| Fluarix Young Group | Haemagglutinin Inhibition (HI) Antibody Titers | B/Brisbane strain at Day 21 | 1229.4 titer |
| Fluarix Young Group | Haemagglutinin Inhibition (HI) Antibody Titers | A/Uruguay strain at Day 21 | 179.0 titer |
| Fluarix Young Group | Haemagglutinin Inhibition (HI) Antibody Titers | A/Uruguay strain at Day 42 | 130.3 titer |
| Fluarix Young Group | Haemagglutinin Inhibition (HI) Antibody Titers | A/Uruguay strain at Day 180 | 74.4 titer |
| Fluarix Young Group | Haemagglutinin Inhibition (HI) Antibody Titers | B/Brisbane strain at Day 42 | 971.6 titer |
| Fluarix Young Group | Haemagglutinin Inhibition (HI) Antibody Titers | A/Brisbane strain at Day 0 | 20.5 titer |
| Fluarix Young Group | Haemagglutinin Inhibition (HI) Antibody Titers | A/Brisbane strain at Day 21 | 220.8 titer |
| Fluarix Young Group | Haemagglutinin Inhibition (HI) Antibody Titers | B/Brisbane strain at Day 0 | 169.0 titer |
| Fluarix Young Group | Haemagglutinin Inhibition (HI) Antibody Titers | A/Brisbane strain at Day 42 | 181.4 titer |
| Fluarix Young Group | Haemagglutinin Inhibition (HI) Antibody Titers | B/Brisbane strain at Day 180 | 677.2 titer |
Secondary
HI Antibody Seroconversion Factors
Seroconversion factors were defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0.
Time frame: At Day 21, 42 and 180
Population: The analysis was performed on According-to-Protocol (ATP) immunogenicity cohort which included all evaluable subjects for whom data concerning immunogenicity data were available.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| New Generation Influenza Vaccine GSK2186877A Group | HI Antibody Seroconversion Factors | A/Uruguay strain at Day 21 | 15.5 fold increase |
| New Generation Influenza Vaccine GSK2186877A Group | HI Antibody Seroconversion Factors | B/Brisbane strain at Day 180 | 2.8 fold increase |
| New Generation Influenza Vaccine GSK2186877A Group | HI Antibody Seroconversion Factors | A/Uruguay strain at Day 180 | 5.5 fold increase |
| New Generation Influenza Vaccine GSK2186877A Group | HI Antibody Seroconversion Factors | A/Uruguay strain at Day 42 | 12.2 fold increase |
| New Generation Influenza Vaccine GSK2186877A Group | HI Antibody Seroconversion Factors | A/Brisbane strain at Day 21 | 6.4 fold increase |
| New Generation Influenza Vaccine GSK2186877A Group | HI Antibody Seroconversion Factors | B/Brisbane strain at Day 42 | 5.4 fold increase |
| New Generation Influenza Vaccine GSK2186877A Group | HI Antibody Seroconversion Factors | A/Brisbane strain at Day 180 | 2.3 fold increase |
| New Generation Influenza Vaccine GSK2186877A Group | HI Antibody Seroconversion Factors | A/Brisbane strain at Day 42 | 5.1 fold increase |
| New Generation Influenza Vaccine GSK2186877A Group | HI Antibody Seroconversion Factors | B/Brisbane strain at Day 21 | 7.6 fold increase |
| Fluarix Elderly Group | HI Antibody Seroconversion Factors | A/Uruguay strain at Day 42 | 6.4 fold increase |
| Fluarix Elderly Group | HI Antibody Seroconversion Factors | A/Brisbane strain at Day 21 | 4.7 fold increase |
| Fluarix Elderly Group | HI Antibody Seroconversion Factors | A/Brisbane strain at Day 42 | 3.9 fold increase |
| Fluarix Elderly Group | HI Antibody Seroconversion Factors | A/Brisbane strain at Day 180 | 2.2 fold increase |
| Fluarix Elderly Group | HI Antibody Seroconversion Factors | A/Uruguay strain at Day 21 | 9.4 fold increase |
| Fluarix Elderly Group | HI Antibody Seroconversion Factors | A/Uruguay strain at Day 180 | 3.4 fold increase |
| Fluarix Elderly Group | HI Antibody Seroconversion Factors | B/Brisbane strain at Day 21 | 5.2 fold increase |
| Fluarix Elderly Group | HI Antibody Seroconversion Factors | B/Brisbane strain at Day 42 | 4.1 fold increase |
| Fluarix Elderly Group | HI Antibody Seroconversion Factors | B/Brisbane strain at Day 180 | 2.5 fold increase |
| Fluarix Young Group | HI Antibody Seroconversion Factors | A/Brisbane strain at Day 180 | 4.6 fold increase |
| Fluarix Young Group | HI Antibody Seroconversion Factors | A/Brisbane strain at Day 21 | 10.6 fold increase |
| Fluarix Young Group | HI Antibody Seroconversion Factors | B/Brisbane strain at Day 21 | 7.4 fold increase |
| Fluarix Young Group | HI Antibody Seroconversion Factors | A/Brisbane strain at Day 42 | 8.9 fold increase |
| Fluarix Young Group | HI Antibody Seroconversion Factors | B/Brisbane strain at Day 180 | 4.0 fold increase |
| Fluarix Young Group | HI Antibody Seroconversion Factors | A/Uruguay strain at Day 42 | 7.9 fold increase |
| Fluarix Young Group | HI Antibody Seroconversion Factors | A/Uruguay strain at Day 21 | 11.3 fold increase |
| Fluarix Young Group | HI Antibody Seroconversion Factors | B/Brisbane strain at Day 42 | 5.8 fold increase |
| Fluarix Young Group | HI Antibody Seroconversion Factors | A/Uruguay strain at Day 180 | 4.5 fold increase |
Secondary
Number of Subjects Reporting Any AEs of Specific Interest (AESI)
AESI for safety monitoring are a subset of AEs that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology. Any was defined as occurrence of any symptom, regardless of intensity or relation to vaccination.
Time frame: Day 0-364
Population: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| New Generation Influenza Vaccine GSK2186877A Group | Number of Subjects Reporting Any AEs of Specific Interest (AESI) | 0 Participants |
| Fluarix Elderly Group | Number of Subjects Reporting Any AEs of Specific Interest (AESI) | 0 Participants |
| Fluarix Young Group | Number of Subjects Reporting Any AEs of Specific Interest (AESI) | 0 Participants |
Secondary
Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs)
Grade 3 ecchymosis, redness and swelling was \>100mm and grade 3 pain was considerable pain at rest, that prevented normal everyday activity.
Time frame: Day 0 -6
Population: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| New Generation Influenza Vaccine GSK2186877A Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any ecchymosis | 2 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 ecchymosis | 0 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any pain | 43 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 pain | 0 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any redness | 5 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 redness | 0 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any swelling | 8 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 swelling | 0 Participants |
| Fluarix Elderly Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any pain | 15 Participants |
| Fluarix Elderly Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any swelling | 1 Participants |
| Fluarix Elderly Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 pain | 0 Participants |
| Fluarix Elderly Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any redness | 0 Participants |
| Fluarix Elderly Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 redness | 0 Participants |
| Fluarix Elderly Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any ecchymosis | 1 Participants |
| Fluarix Elderly Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 ecchymosis | 0 Participants |
| Fluarix Elderly Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 swelling | 0 Participants |
| Fluarix Young Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any pain | 35 Participants |
| Fluarix Young Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 ecchymosis | 0 Participants |
| Fluarix Young Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any ecchymosis | 0 Participants |
| Fluarix Young Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 pain | 0 Participants |
| Fluarix Young Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any swelling | 0 Participants |
| Fluarix Young Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 redness | 0 Participants |
| Fluarix Young Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Any redness | 0 Participants |
| Fluarix Young Group | Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events (AEs) | Grade 3 swelling | 0 Participants |
Secondary
Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs)
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom, regardless of intensity or relation to vaccination and related was event assessed by investigator as causally related to the study vaccination.
Time frame: Day 0-364
Population: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| New Generation Influenza Vaccine GSK2186877A Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) | 5 Participants |
| Fluarix Elderly Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) | 11 Participants |
| Fluarix Young Group | Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs) | 1 Participants |
Secondary
Number of Subjects Reporting Any, Grade 3 and Related AEs With a Medically Attended Visit (MAEs)
For each solicited and unsolicited AE the subject experienced, the subject was asked if they received medical attention defined as hospitalization, an emergency room visit or a visit to or from medical personnel (medical doctor) for any reason. Any was defined as occurrence of any symptom, regardless of intensity or relation to vaccination, grade 3 was defined as symptom that prevented normal activity and related was event assessed by investigator as causally related to the study vaccination.
Time frame: Day 0-179
Population: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| New Generation Influenza Vaccine GSK2186877A Group | Number of Subjects Reporting Any, Grade 3 and Related AEs With a Medically Attended Visit (MAEs) | Grade 3 MAE(s) | 4 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | Number of Subjects Reporting Any, Grade 3 and Related AEs With a Medically Attended Visit (MAEs) | Any MAE(s) | 24 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | Number of Subjects Reporting Any, Grade 3 and Related AEs With a Medically Attended Visit (MAEs) | Related MAE(s) | 0 Participants |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related AEs With a Medically Attended Visit (MAEs) | Grade 3 MAE(s) | 9 Participants |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related AEs With a Medically Attended Visit (MAEs) | Any MAE(s) | 21 Participants |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related AEs With a Medically Attended Visit (MAEs) | Related MAE(s) | 0 Participants |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related AEs With a Medically Attended Visit (MAEs) | Any MAE(s) | 13 Participants |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related AEs With a Medically Attended Visit (MAEs) | Related MAE(s) | 0 Participants |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related AEs With a Medically Attended Visit (MAEs) | Grade 3 MAE(s) | 3 Participants |
Secondary
Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs
Any fever was defined as oral temperature ≥ 38.0 degree centigrade (°C), grade 3 fever was defined as oral temperature ≥ 39.0°C. For other symptoms grade 3 was defined as general symptom that prevented normal activity and related was general symptom assessed by the investigator as causally related to the study vaccination.
Time frame: Day 0 -6
Population: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| New Generation Influenza Vaccine GSK2186877A Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 gastrointestinal symptoms | 0 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any arthralgia | 14 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related myalgia | 16 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related gastrointestinal symptoms | 5 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any fatigue | 22 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 myalgia | 0 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any headache | 22 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related fever | 2 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any myalgia | 17 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 headache | 0 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any fever | 2 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related headache | 17 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 fatigue | 0 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 fever | 1 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related shivering | 8 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related fatigue | 21 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related arthralgia | 12 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 shivering | 0 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any gastrointestinal symptoms | 6 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 arthralgia | 0 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any shivering | 11 Participants |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any fever | 0 Participants |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any arthralgia | 3 Participants |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 arthralgia | 0 Participants |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related arthralgia | 1 Participants |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any fatigue | 12 Participants |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 fatigue | 0 Participants |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related fatigue | 8 Participants |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any gastrointestinal symptoms | 4 Participants |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 gastrointestinal symptoms | 0 Participants |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related gastrointestinal symptoms | 1 Participants |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any headache | 7 Participants |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 headache | 0 Participants |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related headache | 2 Participants |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any myalgia | 8 Participants |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 myalgia | 0 Participants |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related myalgia | 7 Participants |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any shivering | 0 Participants |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 shivering | 0 Participants |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related shivering | 0 Participants |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 fever | 0 Participants |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related fever | 0 Participants |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 gastrointestinal symptoms | 0 Participants |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 arthralgia | 0 Participants |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related myalgia | 9 Participants |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any gastrointestinal symptoms | 6 Participants |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related fever | 0 Participants |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any shivering | 2 Participants |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related fatigue | 11 Participants |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 fever | 0 Participants |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 shivering | 1 Participants |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 fatigue | 0 Participants |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any arthralgia | 4 Participants |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related shivering | 1 Participants |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 headache | 0 Participants |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any fatigue | 21 Participants |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related headache | 7 Participants |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any headache | 14 Participants |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related arthralgia | 3 Participants |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any myalgia | 11 Participants |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Related gastrointestinal symptoms | 4 Participants |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Any fever | 0 Participants |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Solicited General AEs | Grade 3 myalgia | 0 Participants |
Secondary
Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs
Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom, regardless of intensity or relation to vaccination, grade 3 was unsolicited symptom that prevented normal activity and related was event assessed by investigator as causally related to the study vaccination.
Time frame: Day 0-20
Population: The analysis was performed on Total Vaccinated cohort which included all subjects with the vaccine administration documented.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| New Generation Influenza Vaccine GSK2186877A Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Grade 3 AE(s) | 2 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Any AE(s) | 13 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Related AE(s) | 3 Participants |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Grade 3 AE(s) | 2 Participants |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Any AE(s) | 21 Participants |
| Fluarix Elderly Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Related AE(s) | 2 Participants |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Any AE(s) | 15 Participants |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Related AE(s) | 1 Participants |
| Fluarix Young Group | Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AEs | Grade 3 AE(s) | 1 Participants |
Secondary
The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker
The markers assessed were CD40L, IL-2, TNF-α, IFN-γ. The separate vaccine strains tested included A/Brisbane, A/Uruguay, B/Brisbane antigens.
Time frame: At Day 0, 21, 42 and 180
Population: The analysis was based on According-to-Protocol (ATP) Immunogenicity cohort which included all evaluable subjects for whom data concerning immunogenicity data were available.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4-CD40L] D 0 | 387.76 cells per million CD4+ Tcells | Standard Deviation 400.63 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4-CD40L] D 21 | 2817.50 cells per million CD4+ Tcells | Standard Deviation 3166.07 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4-CD40L] D 42 | 2447.37 cells per million CD4+ Tcells | Standard Deviation 1766.85 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4-CD40L] D 180 | 2036.70 cells per million CD4+ Tcells | Standard Deviation 1170.14 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4- IFN-γ] D 0 | 832.47 cells per million CD4+ Tcells | Standard Deviation 798.1 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4- IFN-γ] D 21 | 2305.58 cells per million CD4+ Tcells | Standard Deviation 2712.79 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4- IFN-γ] D 42 | 1775.61 cells per million CD4+ Tcells | Standard Deviation 1464.84 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4- IFN-γ] D 180 | 1495.36 cells per million CD4+ Tcells | Standard Deviation 1031.14 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4-IL-2] D 0 | 1085.32 cells per million CD4+ Tcells | Standard Deviation 930.22 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4-IL-2] D 21 | 2534.86 cells per million CD4+ Tcells | Standard Deviation 3188.65 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4-IL-2] D42 | 2205.91 cells per million CD4+ Tcells | Standard Deviation 1754.74 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4-IL-2] D 180 | 1837.60 cells per million CD4+ Tcells | Standard Deviation 1093.26 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4-TNF-α] D 0 | 874.43 cells per million CD4+ Tcells | Standard Deviation 812.98 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4-TNF-α] D 21 | 2114.47 cells per million CD4+ Tcells | Standard Deviation 2448.22 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4-TNF-α] D 42 | 1741.65 cells per million CD4+ Tcells | Standard Deviation 1350.73 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4-TNF-α] D 180 | 1413.29 cells per million CD4+ Tcells | Standard Deviation 865.27 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4-CD40L] D 0 | 1104.24 cells per million CD4+ Tcells | Standard Deviation 987.15 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4-CD40L] D 21 | 980.10 cells per million CD4+ Tcells | Standard Deviation 937.63 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4-CD40L] D 42 | 771.49 cells per million CD4+ Tcells | Standard Deviation 616.2 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4-CD40L] D 180 | 653.13 cells per million CD4+ Tcells | Standard Deviation 547.36 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4-CD40L] D 0 | 308.73 cells per million CD4+ Tcells | Standard Deviation 316.94 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4-CD40L] D 21 | 805.56 cells per million CD4+ Tcells | Standard Deviation 1066.84 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4-CD40L] D 42 | 592.88 cells per million CD4+ Tcells | Standard Deviation 579.07 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4-CD40L] D 180 | 609.34 cells per million CD4+ Tcells | Standard Deviation 524.5 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4-CD40L] D 0 | 647.94 cells per million CD4+ Tcells | Standard Deviation 581.98 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4-CD40L] D 21 | 1607.98 cells per million CD4+ Tcells | Standard Deviation 1806.43 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4-CD40L] D 42 | 1246.10 cells per million CD4+ Tcells | Standard Deviation 1033.85 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4-CD40L] D 180 | 1011.39 cells per million CD4+ Tcells | Standard Deviation 682.07 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4- IFN-γ] D 0 | 279.24 cells per million CD4+ Tcells | Standard Deviation 337.13 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4- IFN-γ] D 21 | 725.55 cells per million CD4+ Tcells | Standard Deviation 752.84 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4- IFN-γ] D 42 | 572.87 cells per million CD4+ Tcells | Standard Deviation 520.31 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4- IFN-γ] D 180 | 586.26 cells per million CD4+ Tcells | Standard Deviation 474.54 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4- IFN-γ] D 0 | 214.92 cells per million CD4+ Tcells | Standard Deviation 245.84 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4- IFN-γ] D 21 | 641.94 cells per million CD4+ Tcells | Standard Deviation 944.37 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4- IFN-γ] D 42 | 458.72 cells per million CD4+ Tcells | Standard Deviation 501.32 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4- IFN-γ] D 180 | 426.59 cells per million CD4+ Tcells | Standard Deviation 418.38 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4- IFN-γ] D 0 | 342.59 cells per million CD4+ Tcells | Standard Deviation 532.27 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4- IFN-γ] D 21 | 1219.72 cells per million CD4+ Tcells | Standard Deviation 1581.26 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4- IFN-γ] D 42 | 903.71 cells per million CD4+ Tcells | Standard Deviation 918.49 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4- IFN-γ] D 180 | 697.03 cells per million CD4+ Tcells | Standard Deviation 635.8 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4-IL2] D 0 | 346.00 cells per million CD4+ Tcells | Standard Deviation 369.76 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4-IL2] D 21 | 872.32 cells per million CD4+ Tcells | Standard Deviation 897.7 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4-IL2] D 42 | 696.36 cells per million CD4+ Tcells | Standard Deviation 598.29 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4-IL2] D 180 | 570.30 cells per million CD4+ Tcells | Standard Deviation 503.83 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4-IL2] D 0 | 278.66 cells per million CD4+ Tcells | Standard Deviation 306.46 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4-IL2] D 21 | 680.16 cells per million CD4+ Tcells | Standard Deviation 1060.47 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4-IL2] D 42 | 534.07 cells per million CD4+ Tcells | Standard Deviation 579.96 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4-IL2] D 180 | 526.12 cells per million CD4+ Tcells | Standard Deviation 483.57 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4-IL2] D 0 | 587.16 cells per million CD4+ Tcells | Standard Deviation 566.46 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4-IL2] D 21 | 1496.41 cells per million CD4+ Tcells | Standard Deviation 1826.01 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4-IL2] D 42 | 1144.72 cells per million CD4+ Tcells | Standard Deviation 1021.68 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4-IL2] D 180 | 933.06 cells per million CD4+ Tcells | Standard Deviation 660.87 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4-TNF-α] D 0 | 262.44 cells per million CD4+ Tcells | Standard Deviation 349.53 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4-TNF-α] D 21 | 621.35 cells per million CD4+ Tcells | Standard Deviation 746.04 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4-TNF-α] D 42 | 500.13 cells per million CD4+ Tcells | Standard Deviation 518.12 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4-TNF-α] D 180 | 462.60 cells per million CD4+ Tcells | Standard Deviation 402.23 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4-TNF-α] D 0 | 223.83 cells per million CD4+ Tcells | Standard Deviation 292.61 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4-TNF-α] D 21 | 600.99 cells per million CD4+ Tcells | Standard Deviation 932.13 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4-TNF-α] D 42 | 452.35 cells per million CD4+ Tcells | Standard Deviation 515.5 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4-TNF-α] D 180 | 370.86 cells per million CD4+ Tcells | Standard Deviation 415.54 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4-TNF-α] D 0 | 414.10 cells per million CD4+ Tcells | Standard Deviation 472.2 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4-TNF-α] D 21 | 967.79 cells per million CD4+ Tcells | Standard Deviation 1226.62 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4-TNF-α] D 42 | 775.92 cells per million CD4+ Tcells | Standard Deviation 756.63 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4-TNF-α] D 180 | 642.05 cells per million CD4+ Tcells | Standard Deviation 520.83 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4-CD40L] D 21 | 451.52 cells per million CD4+ Tcells | Standard Deviation 459.24 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4-TNF-α] D 180 | 230.70 cells per million CD4+ Tcells | Standard Deviation 241.03 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4-CD40L] D 42 | 286.06 cells per million CD4+ Tcells | Standard Deviation 333.05 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4-IL2] D 42 | 724.10 cells per million CD4+ Tcells | Standard Deviation 593.13 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4-CD40L] D 180 | 298.70 cells per million CD4+ Tcells | Standard Deviation 295.58 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4-CD40L] D 0 | 515.89 cells per million CD4+ Tcells | Standard Deviation 566.11 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4-CD40L] D 21 | 1077.12 cells per million CD4+ Tcells | Standard Deviation 990.77 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4-IL2] D 180 | 704.18 cells per million CD4+ Tcells | Standard Deviation 602.5 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4-CD40L] D 42 | 763.04 cells per million CD4+ Tcells | Standard Deviation 606.04 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4-CD40L] D 180 | 757.17 cells per million CD4+ Tcells | Standard Deviation 611.01 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4- IFN-γ] D 0 | 258.94 cells per million CD4+ Tcells | Standard Deviation 258.55 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4-TNF-α] D 0 | 247.22 cells per million CD4+ Tcells | Standard Deviation 274.83 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4- IFN-γ] D 21 | 344.39 cells per million CD4+ Tcells | Standard Deviation 447.19 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4- IFN-γ] D 42 | 326.66 cells per million CD4+ Tcells | Standard Deviation 322.73 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4-TNF-α] D 0 | 305.51 cells per million CD4+ Tcells | Standard Deviation 516.15 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4- IFN-γ] D 180 | 363.03 cells per million CD4+ Tcells | Standard Deviation 361.43 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4-TNF-α] D 21 | 289.38 cells per million CD4+ Tcells | Standard Deviation 376.07 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4- IFN-γ] D 0 | 164.78 cells per million CD4+ Tcells | Standard Deviation 199 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4- IFN-γ] D 21 | 314.63 cells per million CD4+ Tcells | Standard Deviation 311.72 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4- IFN-γ] D 42 | 246.18 cells per million CD4+ Tcells | Standard Deviation 227.8 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4-TNF-α] D 42 | 238.28 cells per million CD4+ Tcells | Standard Deviation 329.62 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4- IFN-γ] D 180 | 228.06 cells per million CD4+ Tcells | Standard Deviation 215.33 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4- IFN-γ] D 0 | 319.38 cells per million CD4+ Tcells | Standard Deviation 507.1 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4- IFN-γ] D 21 | 721.43 cells per million CD4+ Tcells | Standard Deviation 849.49 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4-TNF-α] D 180 | 308.96 cells per million CD4+ Tcells | Standard Deviation 347.12 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4- IFN-γ] D 42 | 517.83 cells per million CD4+ Tcells | Standard Deviation 501.51 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4- IFN-γ] D 180 | 510.37 cells per million CD4+ Tcells | Standard Deviation 539.79 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4-TNF-α] D 21 | 639.74 cells per million CD4+ Tcells | Standard Deviation 663.66 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4-IL2] D 0 | 319.16 cells per million CD4+ Tcells | Standard Deviation 331.16 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4-TNF-α] D 0 | 191.52 cells per million CD4+ Tcells | Standard Deviation 234.42 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4-IL2] D 21 | 427.26 cells per million CD4+ Tcells | Standard Deviation 664.07 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4-IL2] D 42 | 393.67 cells per million CD4+ Tcells | Standard Deviation 460.81 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4-CD40L] D 0 | 1211.72 cells per million CD4+ Tcells | Standard Deviation 1086.88 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4-CD40L] D 21 | 1935.66 cells per million CD4+ Tcells | Standard Deviation 1597.56 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4-IL2] D 180 | 387.63 cells per million CD4+ Tcells | Standard Deviation 429.61 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4-CD40L] D 42 | 1425.02 cells per million CD4+ Tcells | Standard Deviation 1082.35 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4-CD40L] D 180 | 1416.78 cells per million CD4+ Tcells | Standard Deviation 973.63 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4-TNF-α] D 21 | 320.59 cells per million CD4+ Tcells | Standard Deviation 308.63 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4- IFN-γ] D 0 | 835.22 cells per million CD4+ Tcells | Standard Deviation 1598.81 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4-IL2] D 0 | 240.26 cells per million CD4+ Tcells | Standard Deviation 261.18 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4- IFN-γ] D 21 | 1341.17 cells per million CD4+ Tcells | Standard Deviation 1195.01 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4- IFN-γ] D 42 | 997.25 cells per million CD4+ Tcells | Standard Deviation 818.08 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4- IFN-γ] D 180 | 1019.64 cells per million CD4+ Tcells | Standard Deviation 790.42 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4-IL2] D 21 | 391.84 cells per million CD4+ Tcells | Standard Deviation 425.96 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4-IL-2] D 0 | 1119.34 cells per million CD4+ Tcells | Standard Deviation 1002.46 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4-IL-2] D 21 | 1779.41 cells per million CD4+ Tcells | Standard Deviation 1595.66 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4-TNF-α] D 180 | 475.44 cells per million CD4+ Tcells | Standard Deviation 511.57 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4-IL-2] D42 | 1310.05 cells per million CD4+ Tcells | Standard Deviation 1062.08 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4-IL2] D 42 | 295.90 cells per million CD4+ Tcells | Standard Deviation 322.75 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4-IL-2] D 180 | 1285.14 cells per million CD4+ Tcells | Standard Deviation 955.76 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4-TNF-α] D 0 | 928.86 cells per million CD4+ Tcells | Standard Deviation 1924.68 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4-TNF-α] D 42 | 211.12 cells per million CD4+ Tcells | Standard Deviation 267.39 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4-TNF-α] D 21 | 1284.20 cells per million CD4+ Tcells | Standard Deviation 1080.26 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4-IL2] D 180 | 299.67 cells per million CD4+ Tcells | Standard Deviation 274.2 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4-TNF-α] D 42 | 1012.42 cells per million CD4+ Tcells | Standard Deviation 805.86 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4-TNF-α] D 180 | 1015.29 cells per million CD4+ Tcells | Standard Deviation 830.38 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4-CD40L] D 0 | 320.29 cells per million CD4+ Tcells | Standard Deviation 338.91 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4-IL2] D 0 | 451.89 cells per million CD4+ Tcells | Standard Deviation 549.6 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4-CD40L] D 21 | 462.64 cells per million CD4+ Tcells | Standard Deviation 676.17 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4-CD40L] D 42 | 365.94 cells per million CD4+ Tcells | Standard Deviation 474.72 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4-TNF-α] D 42 | 413.38 cells per million CD4+ Tcells | Standard Deviation 490.41 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4-CD40L] D 180 | 466.55 cells per million CD4+ Tcells | Standard Deviation 429.28 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4-IL2] D 21 | 1004.17 cells per million CD4+ Tcells | Standard Deviation 966.2 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4-CD40L] D 0 | 227.76 cells per million CD4+ Tcells | Standard Deviation 266.35 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4-IL2] D 42 | 720.28 cells per million CD4+ Tcells | Standard Deviation 468.43 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4-CD40L] D 21 | 602.51 cells per million CD4+ Tcells | Standard Deviation 431.82 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4-IL-2] D42 | 2199.18 cells per million CD4+ Tcells | Standard Deviation 1251.48 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4-CD40L] D 0 | 1879.85 cells per million CD4+ Tcells | Standard Deviation 963.74 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4-CD40L] D 42 | 417.15 cells per million CD4+ Tcells | Standard Deviation 468.52 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4-TNF-α] D 21 | 1057.83 cells per million CD4+ Tcells | Standard Deviation 507.15 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4-TNF-α] D 42 | 333.52 cells per million CD4+ Tcells | Standard Deviation 375.97 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4-CD40L] D 180 | 584.68 cells per million CD4+ Tcells | Standard Deviation 446.49 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4-IL2] D 42 | 1322.64 cells per million CD4+ Tcells | Standard Deviation 664.52 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4-CD40L] D 21 | 2929.86 cells per million CD4+ Tcells | Standard Deviation 1644.61 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4-CD40L] D 0 | 1129.44 cells per million CD4+ Tcells | Standard Deviation 573.4 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4-TNF-α] D 180 | 477.18 cells per million CD4+ Tcells | Standard Deviation 355.92 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4-CD40L] D 42 | 818.54 cells per million CD4+ Tcells | Standard Deviation 522.72 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4-CD40L] D 21 | 1737.45 cells per million CD4+ Tcells | Standard Deviation 842.62 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4-IL-2] D 180 | 2302.51 cells per million CD4+ Tcells | Standard Deviation 1042.85 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4-CD40L] D 42 | 2436.43 cells per million CD4+ Tcells | Standard Deviation 1365.81 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4-CD40L] D 42 | 1472.48 cells per million CD4+ Tcells | Standard Deviation 725.44 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4-IL2] D 180 | 1439.92 cells per million CD4+ Tcells | Standard Deviation 753.9 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4-IL2] D 180 | 817.80 cells per million CD4+ Tcells | Standard Deviation 470.25 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4-CD40L] D 180 | 1570.98 cells per million CD4+ Tcells | Standard Deviation 843.76 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4-TNF-α] D 42 | 953.30 cells per million CD4+ Tcells | Standard Deviation 491.5 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4-IL2] D 42 | 438.09 cells per million CD4+ Tcells | Standard Deviation 401.87 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4- IFN-γ] D 0 | 563.26 cells per million CD4+ Tcells | Standard Deviation 323.39 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4-CD40L] D 180 | 2619.74 cells per million CD4+ Tcells | Standard Deviation 1167.44 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4-CD40L] D 0 | 750.57 cells per million CD4+ Tcells | Standard Deviation 435.67 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4- IFN-γ] D 21 | 680.40 cells per million CD4+ Tcells | Standard Deviation 543.42 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4-TNF-α] D 0 | 536.34 cells per million CD4+ Tcells | Standard Deviation 369.21 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4-TNF-α] D 0 | 1425.50 cells per million CD4+ Tcells | Standard Deviation 768.88 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4- IFN-γ] D 42 | 623.21 cells per million CD4+ Tcells | Standard Deviation 409.74 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4- IFN-γ] D 0 | 1403.57 cells per million CD4+ Tcells | Standard Deviation 777.81 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4-CD40L] D 0 | 384.02 cells per million CD4+ Tcells | Standard Deviation 397.54 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4- IFN-γ] D 180 | 773.40 cells per million CD4+ Tcells | Standard Deviation 486.08 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4-IL2] D 21 | 1592.61 cells per million CD4+ Tcells | Standard Deviation 810.35 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4- IFN-γ] D 21 | 2258.27 cells per million CD4+ Tcells | Standard Deviation 1307.01 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4- IFN-γ] D 0 | 283.81 cells per million CD4+ Tcells | Standard Deviation 267.71 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4-TNF-α] D 21 | 497.77 cells per million CD4+ Tcells | Standard Deviation 499.72 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4-IL2] D 0 | 369.77 cells per million CD4+ Tcells | Standard Deviation 322.49 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4- IFN-γ] D 21 | 403.00 cells per million CD4+ Tcells | Standard Deviation 355.57 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4-TNF-α] D 0 | 773.44 cells per million CD4+ Tcells | Standard Deviation 420.89 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4-TNF-α] D 21 | 1999.07 cells per million CD4+ Tcells | Standard Deviation 1010.68 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4- IFN-γ] D 42 | 331.47 cells per million CD4+ Tcells | Standard Deviation 356.93 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4- IFN-γ] D 42 | 1849.44 cells per million CD4+ Tcells | Standard Deviation 1124.86 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4-TNF-α] D 21 | 411.24 cells per million CD4+ Tcells | Standard Deviation 333.5 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4- IFN-γ] D 180 | 451.90 cells per million CD4+ Tcells | Standard Deviation 400.61 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4-TNF-α] D 42 | 564.91 cells per million CD4+ Tcells | Standard Deviation 395.51 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4-CD40L] D 21 | 919.30 cells per million CD4+ Tcells | Standard Deviation 679.26 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4- IFN-γ] D 0 | 824.76 cells per million CD4+ Tcells | Standard Deviation 496.44 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4-TNF-α] D 180 | 1051.51 cells per million CD4+ Tcells | Standard Deviation 664.61 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4- IFN-γ] D 180 | 2102.93 cells per million CD4+ Tcells | Standard Deviation 1074.53 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4- IFN-γ] D 21 | 1361.31 cells per million CD4+ Tcells | Standard Deviation 712.84 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4-IL2] D 0 | 1019.08 cells per million CD4+ Tcells | Standard Deviation 512.69 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4-TNF-α] D 42 | 1752.99 cells per million CD4+ Tcells | Standard Deviation 933.9 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4- IFN-γ] D 42 | 1095.12 cells per million CD4+ Tcells | Standard Deviation 676.34 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4-TNF-α] D 180 | 616.75 cells per million CD4+ Tcells | Standard Deviation 383.7 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4-IL-2] D 0 | 1717.41 cells per million CD4+ Tcells | Standard Deviation 852.57 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | B/Brisbane strain[CD4- IFN-γ] D 180 | 1253.33 cells per million CD4+ Tcells | Standard Deviation 862.51 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4-IL2] D 21 | 510.88 cells per million CD4+ Tcells | Standard Deviation 385.11 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4-IL2] D 180 | 514.55 cells per million CD4+ Tcells | Standard Deviation 404.73 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4-IL2] D 0 | 677.11 cells per million CD4+ Tcells | Standard Deviation 397.23 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4-IL-2] D 21 | 2690.36 cells per million CD4+ Tcells | Standard Deviation 1583.12 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4-CD40L] D 180 | 922.06 cells per million CD4+ Tcells | Standard Deviation 511.19 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Brisbane strain[CD4-IL2] D 21 | 816.95 cells per million CD4+ Tcells | Standard Deviation 655.93 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | A/Uruguay strain[CD4-TNF-α] D 0 | 284.69 cells per million CD4+ Tcells | Standard Deviation 317.94 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Producing Each of the Immune Markers Plus Another Immune Marker | pooled strain[CD4-TNF-α] D 180 | 1821.04 cells per million CD4+ Tcells | Standard Deviation 880.59 |
Secondary
The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers
The markers assessed were CD40L, IL-2, TNF-α, IFN-γ. The separate vaccine strains tested included A/Brisbane, A/Uruguay, B/Brisbane antigens.
Time frame: At Day 0, 21, 42 and 180
Population: Analysis was performed on According-to-Protocol (ATP) Immunogenicity cohort. This cohort included all evaluable subjects for whom data concerning immunogenicity were available.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | A/Brisbane vaccine strain Day 0 | 402.28 cells per million CD4+ Tcells | Standard Deviation 421.64 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | pooled vaccine strain Day 21 | 3371.11 cells per million CD4+ Tcells | Standard Deviation 3602.15 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | pooled vaccine strain Day 42 | 2657.07 cells per million CD4+ Tcells | Standard Deviation 1903.38 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | pooled vaccine strain Day 180 | 2105.66 cells per million CD4+ Tcells | Standard Deviation 1232.8 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | pooled vaccine strain Day 0 | 1269.34 cells per million CD4+ Tcells | Standard Deviation 1032.6 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | A/Brisbane vaccine strain Day 21 | 1062.79 cells per million CD4+ Tcells | Standard Deviation 1049.87 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | A/Brisbane vaccine strain Day 42 | 822.07 cells per million CD4+ Tcells | Standard Deviation 667.91 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | A/Brisbane vaccine strain Day 180 | 669.67 cells per million CD4+ Tcells | Standard Deviation 579.75 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | A/Uruguay vaccine strain Day 0 | 342.58 cells per million CD4+ Tcells | Standard Deviation 340.83 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | A/Uruguay vaccine strain Day 21 | 930.98 cells per million CD4+ Tcells | Standard Deviation 1262.81 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | A/Uruguay vaccine strain Day 42 | 678.88 cells per million CD4+ Tcells | Standard Deviation 669.99 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | A/Uruguay vaccine strain Day 180 | 640.97 cells per million CD4+ Tcells | Standard Deviation 567.7 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | B/Brisbane vaccine strain Day 0 | 672.58 cells per million CD4+ Tcells | Standard Deviation 615.67 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | B/Brisbane vaccine strain Day 21 | 1755.55 cells per million CD4+ Tcells | Standard Deviation 1961.87 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | B/Brisbane vaccine strain Day 42 | 1325.35 cells per million CD4+ Tcells | Standard Deviation 1094.01 |
| New Generation Influenza Vaccine GSK2186877A Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | B/Brisbane vaccine strain Day 180 | 1034.78 cells per million CD4+ Tcells | Standard Deviation 725.84 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | A/Brisbane vaccine strain Day 21 | 462.34 cells per million CD4+ Tcells | Standard Deviation 712.32 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | A/Brisbane vaccine strain Day 42 | 392.04 cells per million CD4+ Tcells | Standard Deviation 498.81 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | A/Brisbane vaccine strain Day 180 | 463.94 cells per million CD4+ Tcells | Standard Deviation 458.04 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | B/Brisbane vaccine strain Day 21 | 1149.98 cells per million CD4+ Tcells | Standard Deviation 1032.36 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | A/Uruguay vaccine strain Day 0 | 274.47 cells per million CD4+ Tcells | Standard Deviation 282.29 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | A/Uruguay vaccine strain Day 21 | 497.49 cells per million CD4+ Tcells | Standard Deviation 479.98 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | B/Brisbane vaccine strain Day 180 | 778.13 cells per million CD4+ Tcells | Standard Deviation 630.32 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | A/Uruguay vaccine strain Day 42 | 331.62 cells per million CD4+ Tcells | Standard Deviation 365.4 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | pooled vaccine strain Day 0 | 1309.30 cells per million CD4+ Tcells | Standard Deviation 2098.97 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | B/Brisbane vaccine strain Day 42 | 807.46 cells per million CD4+ Tcells | Standard Deviation 639.01 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | pooled vaccine strain Day 21 | 2108.10 cells per million CD4+ Tcells | Standard Deviation 1728.38 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | A/Uruguay vaccine strain Day 180 | 331.02 cells per million CD4+ Tcells | Standard Deviation 324.69 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | pooled vaccine strain Day 42 | 1540.08 cells per million CD4+ Tcells | Standard Deviation 1138.94 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | pooled vaccine strain Day 180 | 1484.11 cells per million CD4+ Tcells | Standard Deviation 1024.53 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | A/Brisbane vaccine strain Day 0 | 340.57 cells per million CD4+ Tcells | Standard Deviation 352.55 |
| Fluarix Elderly Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | B/Brisbane vaccine strain Day 0 | 504.36 cells per million CD4+ Tcells | Standard Deviation 588.82 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | A/Uruguay vaccine strain Day 42 | 473.17 cells per million CD4+ Tcells | Standard Deviation 500.92 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | A/Brisbane vaccine strain Day 21 | 982.18 cells per million CD4+ Tcells | Standard Deviation 727.7 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | B/Brisbane vaccine strain Day 0 | 1183.48 cells per million CD4+ Tcells | Standard Deviation 582.67 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | pooled vaccine strain Day 42 | 2669.41 cells per million CD4+ Tcells | Standard Deviation 1391.7 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | A/Brisbane vaccine strain Day 42 | 874.34 cells per million CD4+ Tcells | Standard Deviation 544.91 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | B/Brisbane vaccine strain Day 180 | 1640.71 cells per million CD4+ Tcells | Standard Deviation 897.14 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | pooled vaccine strain Day 0 | 2026.14 cells per million CD4+ Tcells | Standard Deviation 1004.93 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | A/Brisbane vaccine strain Day 180 | 973.29 cells per million CD4+ Tcells | Standard Deviation 555.34 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | A/Uruguay vaccine strain Day 180 | 654.30 cells per million CD4+ Tcells | Standard Deviation 503.69 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | A/Brisbane vaccine strain Day 0 | 793.58 cells per million CD4+ Tcells | Standard Deviation 452.84 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | A/Uruguay vaccine strain Day 0 | 437.07 cells per million CD4+ Tcells | Standard Deviation 410.66 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | B/Brisbane vaccine strain Day 21 | 1861.66 cells per million CD4+ Tcells | Standard Deviation 884.81 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | pooled vaccine strain Day 21 | 3228.91 cells per million CD4+ Tcells | Standard Deviation 1714.91 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | A/Uruguay vaccine strain Day 21 | 667.38 cells per million CD4+ Tcells | Standard Deviation 465.08 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | pooled vaccine strain Day 180 | 2746.76 cells per million CD4+ Tcells | Standard Deviation 1232.9 |
| Fluarix Young Group | The GM Number of Influenza-specific CD4 T-cells Per Million CD4+ T-cells Identified After in Vitro Stimulation With Pooled Vaccine Strains and With Each Vaccine Strain Separately Which Were Producing at Least Two Different Markers | B/Brisbane vaccine strain Day 42 | 1572.47 cells per million CD4+ Tcells | Standard Deviation 719.96 |
Secondary
The Number of Subjects Seroconverted to HI Antibodies
Seroconversion was defined as the number of vaccinees who had either a prevaccination titer \< 1:10 and a post-vaccination titer ≥ 1:40 or a pre-vaccination titer ≥ 1:10 and at least a 4-fold increase in post-vaccination titer.
Time frame: At Day 21, 42 and 180
Population: The analysis was performed on According-to-Protocol (ATP) immunogenicity cohort which included all evaluable subjects for whom data concerning immunogenicity data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| New Generation Influenza Vaccine GSK2186877A Group | The Number of Subjects Seroconverted to HI Antibodies | A/Uruguay strain at Day 21 | 52 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | The Number of Subjects Seroconverted to HI Antibodies | B/Brisbane strain at Day 180 | 22 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | The Number of Subjects Seroconverted to HI Antibodies | A/Uruguay strain at Day 180 | 36 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | The Number of Subjects Seroconverted to HI Antibodies | A/Uruguay strain at Day 42 | 48 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | The Number of Subjects Seroconverted to HI Antibodies | A/Brisbane strain at Day 21 | 36 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | The Number of Subjects Seroconverted to HI Antibodies | B/Brisbane strain at Day 42 | 38 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | The Number of Subjects Seroconverted to HI Antibodies | A/Brisbane strain at Day 180 | 16 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | The Number of Subjects Seroconverted to HI Antibodies | A/Brisbane strain at Day 42 | 33 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | The Number of Subjects Seroconverted to HI Antibodies | B/Brisbane strain at Day 21 | 44 Participants |
| Fluarix Elderly Group | The Number of Subjects Seroconverted to HI Antibodies | A/Uruguay strain at Day 42 | 44 Participants |
| Fluarix Elderly Group | The Number of Subjects Seroconverted to HI Antibodies | A/Brisbane strain at Day 21 | 32 Participants |
| Fluarix Elderly Group | The Number of Subjects Seroconverted to HI Antibodies | A/Brisbane strain at Day 42 | 25 Participants |
| Fluarix Elderly Group | The Number of Subjects Seroconverted to HI Antibodies | A/Brisbane strain at Day 180 | 16 Participants |
| Fluarix Elderly Group | The Number of Subjects Seroconverted to HI Antibodies | A/Uruguay strain at Day 21 | 50 Participants |
| Fluarix Elderly Group | The Number of Subjects Seroconverted to HI Antibodies | A/Uruguay strain at Day 180 | 28 Participants |
| Fluarix Elderly Group | The Number of Subjects Seroconverted to HI Antibodies | B/Brisbane strain at Day 21 | 38 Participants |
| Fluarix Elderly Group | The Number of Subjects Seroconverted to HI Antibodies | B/Brisbane strain at Day 42 | 35 Participants |
| Fluarix Elderly Group | The Number of Subjects Seroconverted to HI Antibodies | B/Brisbane strain at Day 180 | 22 Participants |
| Fluarix Young Group | The Number of Subjects Seroconverted to HI Antibodies | A/Brisbane strain at Day 180 | 23 Participants |
| Fluarix Young Group | The Number of Subjects Seroconverted to HI Antibodies | A/Brisbane strain at Day 21 | 29 Participants |
| Fluarix Young Group | The Number of Subjects Seroconverted to HI Antibodies | B/Brisbane strain at Day 21 | 29 Participants |
| Fluarix Young Group | The Number of Subjects Seroconverted to HI Antibodies | A/Brisbane strain at Day 42 | 29 Participants |
| Fluarix Young Group | The Number of Subjects Seroconverted to HI Antibodies | B/Brisbane strain at Day 180 | 20 Participants |
| Fluarix Young Group | The Number of Subjects Seroconverted to HI Antibodies | A/Uruguay strain at Day 42 | 30 Participants |
| Fluarix Young Group | The Number of Subjects Seroconverted to HI Antibodies | A/Uruguay strain at Day 21 | 33 Participants |
| Fluarix Young Group | The Number of Subjects Seroconverted to HI Antibodies | B/Brisbane strain at Day 42 | 25 Participants |
| Fluarix Young Group | The Number of Subjects Seroconverted to HI Antibodies | A/Uruguay strain at Day 180 | 20 Participants |
Secondary
The Number of Subjects Seropositive to HI Antibodies Calculated After in Vitro Stimulation With Separate Vaccine Strains.
Seropositivity was defined as antibody titer greater than or equal to the cut-off value i.e ≥ 1:10
Time frame: At Day 0, 21, 42 and 180
Population: The analysis was performed on According-to-Protocol (ATP) immunogenicity cohort which included all evaluable subjects for whom data concerning immunogenicity data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| New Generation Influenza Vaccine GSK2186877A Group | The Number of Subjects Seropositive to HI Antibodies Calculated After in Vitro Stimulation With Separate Vaccine Strains. | A/Brisbane strain at Day 0 | 43 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | The Number of Subjects Seropositive to HI Antibodies Calculated After in Vitro Stimulation With Separate Vaccine Strains. | A/Brisbane strain at Day 21 | 61 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | The Number of Subjects Seropositive to HI Antibodies Calculated After in Vitro Stimulation With Separate Vaccine Strains. | A/Brisbane strain at Day 42 | 60 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | The Number of Subjects Seropositive to HI Antibodies Calculated After in Vitro Stimulation With Separate Vaccine Strains. | A/Brisbane strain at Day 180 | 57 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | The Number of Subjects Seropositive to HI Antibodies Calculated After in Vitro Stimulation With Separate Vaccine Strains. | A/Uruguay strain at Day 0 | 41 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | The Number of Subjects Seropositive to HI Antibodies Calculated After in Vitro Stimulation With Separate Vaccine Strains. | A/Uruguay strain at Day 21 | 62 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | The Number of Subjects Seropositive to HI Antibodies Calculated After in Vitro Stimulation With Separate Vaccine Strains. | A/Uruguay strain at Day 42 | 60 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | The Number of Subjects Seropositive to HI Antibodies Calculated After in Vitro Stimulation With Separate Vaccine Strains. | A/Uruguay strain at Day 180 | 61 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | The Number of Subjects Seropositive to HI Antibodies Calculated After in Vitro Stimulation With Separate Vaccine Strains. | B/Brisbane strain at Day 0 | 59 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | The Number of Subjects Seropositive to HI Antibodies Calculated After in Vitro Stimulation With Separate Vaccine Strains. | B/Brisbane strain at Day 21 | 62 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | The Number of Subjects Seropositive to HI Antibodies Calculated After in Vitro Stimulation With Separate Vaccine Strains. | B/Brisbane strain at Day 42 | 61 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | The Number of Subjects Seropositive to HI Antibodies Calculated After in Vitro Stimulation With Separate Vaccine Strains. | B/Brisbane strain at Day 180 | 62 Participants |
| Fluarix Elderly Group | The Number of Subjects Seropositive to HI Antibodies Calculated After in Vitro Stimulation With Separate Vaccine Strains. | B/Brisbane strain at Day 180 | 66 Participants |
| Fluarix Elderly Group | The Number of Subjects Seropositive to HI Antibodies Calculated After in Vitro Stimulation With Separate Vaccine Strains. | A/Brisbane strain at Day 0 | 40 Participants |
| Fluarix Elderly Group | The Number of Subjects Seropositive to HI Antibodies Calculated After in Vitro Stimulation With Separate Vaccine Strains. | A/Uruguay strain at Day 42 | 62 Participants |
| Fluarix Elderly Group | The Number of Subjects Seropositive to HI Antibodies Calculated After in Vitro Stimulation With Separate Vaccine Strains. | B/Brisbane strain at Day 0 | 65 Participants |
| Fluarix Elderly Group | The Number of Subjects Seropositive to HI Antibodies Calculated After in Vitro Stimulation With Separate Vaccine Strains. | A/Brisbane strain at Day 21 | 62 Participants |
| Fluarix Elderly Group | The Number of Subjects Seropositive to HI Antibodies Calculated After in Vitro Stimulation With Separate Vaccine Strains. | A/Uruguay strain at Day 21 | 63 Participants |
| Fluarix Elderly Group | The Number of Subjects Seropositive to HI Antibodies Calculated After in Vitro Stimulation With Separate Vaccine Strains. | B/Brisbane strain at Day 42 | 65 Participants |
| Fluarix Elderly Group | The Number of Subjects Seropositive to HI Antibodies Calculated After in Vitro Stimulation With Separate Vaccine Strains. | A/Brisbane strain at Day 42 | 62 Participants |
| Fluarix Elderly Group | The Number of Subjects Seropositive to HI Antibodies Calculated After in Vitro Stimulation With Separate Vaccine Strains. | A/Uruguay strain at Day 180 | 59 Participants |
| Fluarix Elderly Group | The Number of Subjects Seropositive to HI Antibodies Calculated After in Vitro Stimulation With Separate Vaccine Strains. | A/Uruguay strain at Day 0 | 45 Participants |
| Fluarix Elderly Group | The Number of Subjects Seropositive to HI Antibodies Calculated After in Vitro Stimulation With Separate Vaccine Strains. | A/Brisbane strain at Day 180 | 57 Participants |
| Fluarix Elderly Group | The Number of Subjects Seropositive to HI Antibodies Calculated After in Vitro Stimulation With Separate Vaccine Strains. | B/Brisbane strain at Day 21 | 66 Participants |
| Fluarix Young Group | The Number of Subjects Seropositive to HI Antibodies Calculated After in Vitro Stimulation With Separate Vaccine Strains. | A/Brisbane strain at Day 180 | 40 Participants |
| Fluarix Young Group | The Number of Subjects Seropositive to HI Antibodies Calculated After in Vitro Stimulation With Separate Vaccine Strains. | A/Uruguay strain at Day 0 | 24 Participants |
| Fluarix Young Group | The Number of Subjects Seropositive to HI Antibodies Calculated After in Vitro Stimulation With Separate Vaccine Strains. | B/Brisbane strain at Day 21 | 43 Participants |
| Fluarix Young Group | The Number of Subjects Seropositive to HI Antibodies Calculated After in Vitro Stimulation With Separate Vaccine Strains. | A/Uruguay strain at Day 21 | 41 Participants |
| Fluarix Young Group | The Number of Subjects Seropositive to HI Antibodies Calculated After in Vitro Stimulation With Separate Vaccine Strains. | A/Uruguay strain at Day 42 | 42 Participants |
| Fluarix Young Group | The Number of Subjects Seropositive to HI Antibodies Calculated After in Vitro Stimulation With Separate Vaccine Strains. | A/Uruguay strain at Day 180 | 39 Participants |
| Fluarix Young Group | The Number of Subjects Seropositive to HI Antibodies Calculated After in Vitro Stimulation With Separate Vaccine Strains. | B/Brisbane strain at Day 42 | 44 Participants |
| Fluarix Young Group | The Number of Subjects Seropositive to HI Antibodies Calculated After in Vitro Stimulation With Separate Vaccine Strains. | A/Brisbane strain at Day 0 | 25 Participants |
| Fluarix Young Group | The Number of Subjects Seropositive to HI Antibodies Calculated After in Vitro Stimulation With Separate Vaccine Strains. | A/Brisbane strain at Day 21 | 43 Participants |
| Fluarix Young Group | The Number of Subjects Seropositive to HI Antibodies Calculated After in Vitro Stimulation With Separate Vaccine Strains. | B/Brisbane strain at Day 0 | 42 Participants |
| Fluarix Young Group | The Number of Subjects Seropositive to HI Antibodies Calculated After in Vitro Stimulation With Separate Vaccine Strains. | A/Brisbane strain at Day 42 | 44 Participants |
| Fluarix Young Group | The Number of Subjects Seropositive to HI Antibodies Calculated After in Vitro Stimulation With Separate Vaccine Strains. | B/Brisbane strain at Day 180 | 43 Participants |
Secondary
The Number of Subjects Seroprotected to HI Antibodies
A seroprotected subject was defined as a subject with a serum HI titer greater than or equal to 1:40 that usually is accepted as indicating protection.
Time frame: At Day 0, 21, 42 and 180
Population: The analysis was performed on According-to-Protocol (ATP) immunogenicity cohort which included all evaluable subjects for whom data concerning immunogenicity data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| New Generation Influenza Vaccine GSK2186877A Group | The Number of Subjects Seroprotected to HI Antibodies | A/Brisbane strain at Day 0 | 20 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | The Number of Subjects Seroprotected to HI Antibodies | A/Brisbane strain at Day 21 | 57 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | The Number of Subjects Seroprotected to HI Antibodies | A/Brisbane strain at Day 42 | 56 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | The Number of Subjects Seroprotected to HI Antibodies | A/Brisbane strain at Day 180 | 39 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | The Number of Subjects Seroprotected to HI Antibodies | A/Uruguay strain at Day 0 | 26 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | The Number of Subjects Seroprotected to HI Antibodies | A/Uruguay strain at Day 21 | 61 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | The Number of Subjects Seroprotected to HI Antibodies | A/Uruguay strain at Day 42 | 59 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | The Number of Subjects Seroprotected to HI Antibodies | A/Uruguay strain at Day 180 | 53 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | The Number of Subjects Seroprotected to HI Antibodies | B/Brisbane strain at Day 0 | 51 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | The Number of Subjects Seroprotected to HI Antibodies | B/Brisbane strain at Day 21 | 62 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | The Number of Subjects Seroprotected to HI Antibodies | B/Brisbane strain at Day 42 | 61 Participants |
| New Generation Influenza Vaccine GSK2186877A Group | The Number of Subjects Seroprotected to HI Antibodies | B/Brisbane strain at Day 180 | 60 Participants |
| Fluarix Elderly Group | The Number of Subjects Seroprotected to HI Antibodies | B/Brisbane strain at Day 180 | 65 Participants |
| Fluarix Elderly Group | The Number of Subjects Seroprotected to HI Antibodies | A/Brisbane strain at Day 0 | 16 Participants |
| Fluarix Elderly Group | The Number of Subjects Seroprotected to HI Antibodies | A/Uruguay strain at Day 42 | 53 Participants |
| Fluarix Elderly Group | The Number of Subjects Seroprotected to HI Antibodies | B/Brisbane strain at Day 0 | 57 Participants |
| Fluarix Elderly Group | The Number of Subjects Seroprotected to HI Antibodies | A/Brisbane strain at Day 21 | 53 Participants |
| Fluarix Elderly Group | The Number of Subjects Seroprotected to HI Antibodies | A/Uruguay strain at Day 21 | 57 Participants |
| Fluarix Elderly Group | The Number of Subjects Seroprotected to HI Antibodies | B/Brisbane strain at Day 42 | 64 Participants |
| Fluarix Elderly Group | The Number of Subjects Seroprotected to HI Antibodies | A/Brisbane strain at Day 42 | 47 Participants |
| Fluarix Elderly Group | The Number of Subjects Seroprotected to HI Antibodies | A/Uruguay strain at Day 180 | 48 Participants |
| Fluarix Elderly Group | The Number of Subjects Seroprotected to HI Antibodies | A/Uruguay strain at Day 0 | 24 Participants |
| Fluarix Elderly Group | The Number of Subjects Seroprotected to HI Antibodies | A/Brisbane strain at Day 180 | 34 Participants |
| Fluarix Elderly Group | The Number of Subjects Seroprotected to HI Antibodies | B/Brisbane strain at Day 21 | 65 Participants |
| Fluarix Young Group | The Number of Subjects Seroprotected to HI Antibodies | A/Brisbane strain at Day 180 | 36 Participants |
| Fluarix Young Group | The Number of Subjects Seroprotected to HI Antibodies | A/Uruguay strain at Day 0 | 16 Participants |
| Fluarix Young Group | The Number of Subjects Seroprotected to HI Antibodies | B/Brisbane strain at Day 21 | 43 Participants |
| Fluarix Young Group | The Number of Subjects Seroprotected to HI Antibodies | A/Uruguay strain at Day 21 | 39 Participants |
| Fluarix Young Group | The Number of Subjects Seroprotected to HI Antibodies | A/Uruguay strain at Day 42 | 39 Participants |
| Fluarix Young Group | The Number of Subjects Seroprotected to HI Antibodies | A/Uruguay strain at Day 180 | 33 Participants |
| Fluarix Young Group | The Number of Subjects Seroprotected to HI Antibodies | B/Brisbane strain at Day 42 | 44 Participants |
| Fluarix Young Group | The Number of Subjects Seroprotected to HI Antibodies | A/Brisbane strain at Day 0 | 18 Participants |
| Fluarix Young Group | The Number of Subjects Seroprotected to HI Antibodies | A/Brisbane strain at Day 21 | 42 Participants |
| Fluarix Young Group | The Number of Subjects Seroprotected to HI Antibodies | B/Brisbane strain at Day 0 | 39 Participants |
| Fluarix Young Group | The Number of Subjects Seroprotected to HI Antibodies | A/Brisbane strain at Day 42 | 42 Participants |
| Fluarix Young Group | The Number of Subjects Seroprotected to HI Antibodies | B/Brisbane strain at Day 180 | 42 Participants |